ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE)
University Health Network, Toronto
University Health Network, Toronto
Stanford University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
Roswell Park Cancer Institute
Wake Forest University Health Sciences
St. Jude Children's Research Hospital
University of Turin, Italy
Stanford University
Alliance for Clinical Trials in Oncology
University of Arizona
Ohio State University Comprehensive Cancer Center
Hackensack Meridian Health
H. Lee Moffitt Cancer Center and Research Institute
University of Kansas Medical Center
Augusta University
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
University of California, Irvine
M.D. Anderson Cancer Center
Massachusetts General Hospital
M.D. Anderson Cancer Center
Groupe Francophone des Myelodysplasies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Dartmouth-Hitchcock Medical Center
Children's Hospital Medical Center, Cincinnati
Assiut University
M.D. Anderson Cancer Center
Peking University People's Hospital
City of Hope Medical Center
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
University of Chicago
Baylor College of Medicine
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Rigshospitalet, Denmark
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
St. Petersburg State Pavlov Medical University
Centre Leon Berard
Fred Hutchinson Cancer Center
Case Comprehensive Cancer Center